On Thursday, Navios Maritime Acquisition Corporation (NNA)’s shares gained 5.75%, closed at $3.86.
Last Tuesday, Navios Maritime Acquisition Corporation, declared its Annual Report on Form 20-F for the year ended December 31, 2014 has been filed with the SEC and can be accessed on Navios Attainment’s website www.navios-attainment.com under the “Investors” section.
Navios Maritime Acquisition Corporation, provides marine transportation services worldwide. The corporation owns a fleet of crude oil, refined petroleum product, and chemical tankers.
IHS Inc. (NYSE:IHS)’s shares jumped 5.73%, and settled at $120.33, during the last trading session on Thursday, following the news release that Technology market research firm Infonetics Research, now part of IHS Inc. stated almost 1.2 million 802.11ac access points shipped in the fourth quarter of 2014 (4Q14) — a quarter of all access points — cannibalizing 802.11n rather than the older 802.11a/b/g access points.
Infonetics’ 4Q14 and year-end Wireless LAN Equipment and WiFi Phones market share, size and forecast report tracks enterprise access points, wireless LAN (WLAN) controllers and WiFi phones.
“The good news is that the fourth quarter of 2014 looks to be the turning point. RFP activity from K-12 customers is accelerating in anticipation of new funding in 2015, and that, coupled with the introduction of 802.11ac wave 2 access points, will drive renewed growth in 2015,” Machowinski said.
IHS Inc. provides critical information, insights, and analytics worldwide. The corporation offers solutions in customer workflows, counting strategy, planning, and analysis that provides information, research, and tools, which support a range of commercial decisions and processes comprising capital investments, country-entry strategies, attainments, annual planned planning processes, and monthly/quarterly productions and sales forecasts.
At the end of Thursday’s trade, Triangle Petroleum Corporation (NYSEMKT:TPLM)’s shares climbed 5.33%, and closed at $5.34.
Triangle Petroleum Corporation, has planned the release of its fourth quarter and full fiscal year 2015 financial results for after the close of trading on Monday, April 13, 2015.
Triangle will host a conference call and webcast on Tuesday, April 14, 2015 at 8:30 AM MT (10:30 AM ET) to provide an operational update and talk about the financial results of Triangle’s fourth quarter and full fiscal year 2015, followed right away by a question and answer session. Triangle anticipates to file its annual report on Form 10-K and issue a press release providing an operational update and financial results preceding to the conference call.
Triangle Petroleum Corporation is engaged in the attainment, exploration, development, and production of unconventional shale oil and natural gas resources in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana.
ImmunoGen, Inc. (NASDAQ:IMGN), ended its Thursday’s trading session with 5.20% gain, and closed at $9.40, as a biotechnology corporation, declared the appointment of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. Dr. Berkenblit reports to Dr. Charles Morris, EVP and Chief Development Officer and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. Dr. Berkenblit has extensive experience in the clinical development of novel anticancer therapies, counting five years heading clinical research at two oncology-focused companies.
“We are very happy to welcome Anna to the ImmunoGen team,” commented Dr. Morris. “Anna brings an important depth of experience in the clinical development of novel, targeted anticancer agents. She has directed programs ranging from initial clinical testing to registration-directed trials across a number of cancer types. Her experience will be highly valuable as we prepare to advance our product candidates into later stages of development.”
ImmunoGen, Inc., a biotechnology corporation, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The corporation offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
